COVID-19 in India: Bharat Biotech Asked To Provide More Data on 'Covaxin' for Below 12-Year-Olds
The Corbevax vaccine is currently being administered to children in the age group of 12-14 years.
New Delhi [India], April 22: The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said.
This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years. No recommendations have been made as of now, sources told ANI. Omicron Sub-Variant BA.2.12 of COVID-19 Found in Majority of Delhi Samples, Could Be Behind Surge: Sources.
However, the SEC, after a meeting on Thursday, has recommended restricted emergency use of Biological E's COVID-19 vaccine, Corbevax, in children aged 5-12 years, said sources. Now DCGI will be giving approval for its emergency use authorisation.
The Corbevax vaccine is currently being administered to children in the age group of 12-14 years.
The vaccination drive for children in the age group of 15-18 years commenced on January 3 this year. They are being administered Covaxin.
The drive later expanded on March 16 to include children aged between 12-14 years. They are being administered Corbevax.
Overall, India is currently administering two COVID-19 vaccines to children above 12 years.
(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)